Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

OABI vs VNDA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

OABI Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 7–3 Matrix Metrics)

OABI Overall Winner 6-Pillar Tally: OABI 4 – 1 VNDA (1 Tie) Matrix Metrics: OABI 7 – 3 VNDA

As of Nov 16, 2026, OmniAb, Inc. (OABI) is the stronger overall head-to-head candidate over Vanda Pharmaceuticals Inc. (VNDA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). OABI carries a Unified Composite Score of 50.3/100 (HOLD) at $4.92 (N/M Forward P/E, -92.9% operating margin), whereas VNDA carries 49.0/100 (HOLD) at $3.79 (103.1x Forward P/E, -77.6% operating margin).

  • Technical & Structure Timing Caution: OABI trades in a Markup technical trend (SURGE options phase, RSI 50.1); meanwhile VNDA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About OABI vs VNDA
OABI NASDAQ Head-to-Head Winner
OmniAb, Inc. Common Stock
Services-Commercial Physical & Biological Research
$4.92
+0.1% 1D
Market Cap $722.0M
TTM Revenue $40M
Forward P/E N/M
Beta / 30D Vol 1.25β · 58% Vol
Unified Composite Score
50.3 / 100 HOLD
Tech 33.0 Fund 42.0 Flow 57.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (7.4% over 20 days), RSI 50
RSI-14: 50.1 · SMA20: $5.00 · SMA50: $4.75
VNDA NASDAQ
Vanda Pharmaceuticals Inc.
Pharmaceutical Preparations
$3.79
-4.89% 1D
Market Cap $238.9M
TTM Revenue $229M
Forward P/E 103.1x
Beta / 30D Vol 1.25β · 61% Vol
Unified Composite Score
49.0 / 100 HOLD
Tech 56.0 Fund 58.0 Flow 65.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.9%), weak momentum, RSI 40
RSI-14: 40.0 · SMA20: $3.95 · SMA50: $4.46

6-Pillar Scorecard Institutional Category Breakdown (OABI 4 – 1 VNDA)

Columns: Metric · OABI · VNDA
1. Valuation Multiples VNDA
Forward P/E N/M 103.1x
Trailing P/E N/M 103.1x
PEG Ratio N/M 2.23x
EV / Revenue 17.8x 0.9x
2. Growth & Scale OABI
Revenue Growth (YoY) +78.3% +24.1%
Earnings Growth (YoY) +0.0% -95.9%
TTM Revenue (USD) $40M $229M
Market Cap $722.0M $238.9M
3. Profitability & Quality OABI
Gross Margin 97.7% 93.6%
Operating Margin -92.9% -77.6%
Net Profit Margin -108.1% -119.9%
Return on Equity (ROE) -16.5% -82.5%
4. Balance Sheet & Cash Flow OABI
Cash Generation (TTM) $2.4M -$150M
Cash Flow Margin 5.9% -65.4%
Net Cash / Leverage $4.7M Net Cash $40M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning OABI
Options Structure Phase SURGE BREAKDOWN
Current IV / %ile 93.6% (12th %ile) 163.3% (75th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: OABI (7) vs VNDA (3)
Institutional Metric OABI VNDA Criterion Row Edge
Market Capitalization
Scale
$722.0M $238.9M Larger Scale OABI
Trailing P/E Ratio
Valuation
N/M 103.1x Lower Multiple VNDA
Forward P/E Ratio
Valuation
N/M 103.1x Lower Multiple VNDA
Revenue Growth (YoY)
Growth
+78.3% +24.1% Higher Growth OABI
Operating Margin (TTM)
Profitability
-92.9% -77.6% Higher Margin VNDA
Net Profit Margin
Profitability
-108.1% -119.9% Higher Margin OABI
Return on Equity (ROE)
Capital Efficiency
-16.5% -82.5% Higher ROE OABI
52-Week Range Position
Momentum
87% ($1–$5) 4% ($4–$10) Stronger Trend OABI
Beta / 30D Volatility
Risk Regime
1.25β · 58% Vol 1.25β · 61% Vol Lower Realized Risk OABI
Unified Institutional Score
Composite Signal
50.3 / 100 (HOLD) 49.0 / 100 (HOLD) Higher Composite OABI
Trailing 12M Revenue (USD)
Operating Scale
$40M $229M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
97.7% 93.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 17.8x EV/Rev 2.23x PEG · 0.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$2.4M ($4.7M Net Cash) -$150M ($40M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon OABI +12.91 pp
OABI: +7.08% · VNDA: -5.83%
3M Horizon OABI +55.62 pp
OABI: +25.38% · VNDA: -30.24%
6M Horizon OABI +152.21 pp
OABI: +114.63% · VNDA: -37.58%
1Y Horizon OABI +235.92 pp
OABI: +223.36% · VNDA: -12.56%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period OABI Revenue VNDA Revenue OABI Op. Margin VNDA Op. Margin Margin Leader
FY2018 N/A $190M N/A 11.3% VNDA
FY2019 N/A $230M N/A 10.0% VNDA
FY2020 N/A $250M N/A 11.0% VNDA
FY2021 $30M $270M -102.5% 15.7% VNDA
FY2022 $60M $250M -45.1% 2.5% VNDA
FY2023 $30M $190M -203.2% -7.2% VNDA
FY2024 $30M $200M -282.3% -20.5% VNDA
FY2025 $20M $220M -369.5% -70.0% VNDA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
OABI SURGE
13d in phase · OBV NEUTRAL
Current IV 93.6%
IV Percentile 12th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact OABI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VNDA BREAKDOWN
174d in phase · OBV NEUTRAL
Current IV 163.3%
IV Percentile 75th %ile
Put/Call OI Skew N/A
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact VNDA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
OABI Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $722.0M market capitalization and -92.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
VNDA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $238.9M market capitalization and -77.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ OABI vs VNDA Key Questions & Quantitative Answers

As of Nov 16, 2026, OmniAb, Inc. (OABI) is the stronger overall head-to-head candidate over Vanda Pharmaceuticals Inc. (VNDA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). OABI carries a Unified Composite Score of 50.3/100 (HOLD) at $4.92 (N/M Forward P/E, -92.9% operating margin), whereas VNDA carries 49.0/100 (HOLD) at $3.79 (103.1x Forward P/E, -77.6% operating margin). Technical & Structure Timing Caution: OABI trades in a Markup technical trend (SURGE options phase, RSI 50.1); meanwhile VNDA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

OABI leads the Growth & Scale pillar: OABI posts +78.3% YoY revenue growth and +0.0% YoY earnings growth on $40M TTM revenue (97.7% gross margin, -92.9% operating margin), compared with VNDA at +24.1% YoY revenue growth and -95.9% YoY earnings growth on $229M TTM revenue (93.6% gross margin, -77.6% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), OABI cumulative revenue shifted -33.3% while VNDA shifted +15.8%. In operating R&D and SG&A reinvestment, OABI deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VNDA.

VNDA screens cheaper on headline valuation multiples. OABI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 17.8x EV/Revenue (5.9% FCF margin), whereas VNDA trades at 103.1x Forward P/E, 103.1x Trailing P/E, 2.23x PEG, and 0.9x EV/Revenue (-65.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OABI (-16.5% ROE) versus VNDA (-82.5% ROE) capital efficiency.

In options market volatility and institutional positioning, OABI carries 93.6% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (1.25β · 58% Vol realized risk). By comparison, VNDA carries 163.3% implied volatility (75th %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.25β · 61% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.